, 1997, Sep. 11, Vol. 337(11), 725–733.
25 Gulick R. et al. Treatment with Indinavir, Zidovudine, and Lamivudine in adults with human immunodefciency virus infection and prior antiretroviral therapy // New England Journal of Medicine, 1997, Vol. 337, 734–739.
26 Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies // Lancet, 2008, Vol. 372, 293–299.
27 Weller S., Davis K. Condom effectiveness in reducing heterosexual HIV transmission // The Cochrane Database of Systematic Reviews, 2002.
28 Townsend C. et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011 // AIDS, Apr. 2014, Vol. 28, Issue 7, 1049–1057.
29 Коалиция по готовности к лечению. Закупки АРВ-препаратов в 2014 году: хроника децентрализации. Результаты мониторинга закупок и предоставления АРВ-препаратов в РФ. Санкт-Петербург, 2015. Публикация доступна на сайте http://itpcru.org
30 Hutter G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation // New England Journal of Medicine, Feb. 2009, Vol. 360, 692–698.
31 Hutter G., Thiel E. Allogeneic transplantation of CCR5-defcient progenitor cells in a patient with HIV infection: An update after 3 years and the search for patient no. 2 // AIDS, Jan. 2011, Vol. 25, Issue 2, 273–274.
32 Yukl S. et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient // PLOS Pathogens, May 2013, Vol. 9(5), e1003347.
33 Brown T. I am the Berlin patient: A personal refection // AIDS Research and Human Retroviruses, Jan. 2015, Vol. 31, No. 1, 2–3.
34 Poropatich K., Sullivan D. Human immunodefciency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression // Journal of General Virology, February 2011, Vol. 92, No. 2, 247–268.
35 Saez-Cirion A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study // PLOS Pathogens, Mar. 2013, Vol. 9(3), e1003211.
36 Lehrman G., Hogue I. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study // Lancet, Aug. 2005, Vol. 366(9485), 549–555.
37 Tebas P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV // New England Journal of Medicine, 2014, Vol. 370, 901–910.
38 Caskey M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 //